Analyst Highlights Emerging Pharmaceutical Competitor in the Booming GLP-1 Weight Loss Market

Financial commentator Jim Cramer identifies a lesser-known pharmaceutical candidate poised to capture significant market share alongside established leaders like Eli Lilly in the rapidly expanding weight-loss drug sector.